| Product NDC: | 0069-0151 |
| Proprietary Name: | INLYTA |
| Non Proprietary Name: | AXITINIB |
| Active Ingredient(s): | 5 mg/1 & nbsp; AXITINIB |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, FILM COATED |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0069-0151 |
| Labeler Name: | Pfizer Laboratories Div Pfizer Inc |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA202324 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20120127 |
| Package NDC: | 0069-0151-11 |
| Package Description: | 60 TABLET, FILM COATED in 1 BOTTLE (0069-0151-11) |
| NDC Code | 0069-0151-11 |
| Proprietary Name | INLYTA |
| Package Description | 60 TABLET, FILM COATED in 1 BOTTLE (0069-0151-11) |
| Product NDC | 0069-0151 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | AXITINIB |
| Dosage Form Name | TABLET, FILM COATED |
| Route Name | ORAL |
| Start Marketing Date | 20120127 |
| Marketing Category Name | NDA |
| Labeler Name | Pfizer Laboratories Div Pfizer Inc |
| Substance Name | AXITINIB |
| Strength Number | 5 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Kinase Inhibitor [EPC],Receptor Tyrosine Kinase Inhibitors [MoA] |